参考文献/References:
[1] Lenders JW,Duh QY,Eisenhofer G,et al. Pheochromocytoma and paraganglioma:an endocrine society clinical practice guideline[J].J Clin Endocrinol Metab,2014,99(6):1915-1942.DOI:10.1210/jc.2014-1498.
[2] 中华医学会内分泌学分会肾上腺学组. 嗜铬细胞瘤和副神经节瘤诊断治疗的专家共识[J].中华内分泌代谢杂志,2016,32(3):181-187.DOI:10.3760/cma.j.issn.1000-6699.2016.03.002.
[3] Eisenhofer G,Peitzsch M. Laboratory evaluation of pheochromocytoma and paraganglioma[J].Clin Chem,2014,60(12):1486-1499.DOI:10.1373/clinchem.2014.224832.
[4] Eisenhofer G,Keiser H,Friberg P,et al. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors[J].J Clin Endocrinol Metab,1998,83(6):2175-2185.DOI:10.1210/jcem.83.6.4870.
[5] Lenders JW,Pacak K,Walther MM,et al. Biochemical diagnosis of pheochromocytoma:which test is best?[J].JAMA,2002,287(11):1427-1434.DOI:10.1001/jama.287.11.1427.
[6] Eisenhofer G,Pacak K,Huynh TT,et al. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma[J].Endocr Relat Cancer,2010,18(1):97-111.DOI:10.1677/ERC-10-0211.
[7] Eisenhofer G,Lenders JW,Goldstein DS,et al. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines[J].Clin Chem,2005,51(4):735-744.DOI:10.1373/clinchem.2004.045484.
[8] Van Berkel A,Lenders JW,Timmers HJ. Diagnosis of endocrine disease:biochemical diagnosis of phaeochromocytoma and paraganglioma[J].Eur J Endocrinol,2014,170(3):R109-R119.DOI:10.1530/EJE-13-0882.
[9] Pacak K,Wimalawansa SJ. Pheochromocytoma and paraganglioma[J].Endocr Pract,2015,21(4):406-412.DOI:10.4158/EP14481.
[10] 曹万里,黄宝星,成康,等. 血浆游离甲氧肾上腺素和甲氧基去甲肾上腺素正常的嗜铬细胞瘤/副神经节瘤患者的临床特点[J].中华临床医师杂志(电子版),2015,9(02):200-205. DOI:CNKI:SUN:ZLYD.0.2015-02-005.
[11] Heavner MG,Krane LS,Winters SM,et al. Pheochromocytoma diagnosed pathologically with previous negative serum markers[J].J Surg Oncol,2015,112(5):492-495.DOI:10.1002/jso.24031.
[12] Wang K,Gao X,Cong H,et al. Stability and reference intervals of spot urinary fractionated metanephrines and methoxytyramine by tandem mass spectrometry as a screening method for pheochromocytoma and paraganglioma[J].Endocrine,2020,69(1):188-195.DOI:10.1007/s12020-020-02267-8.
[13] Peitzsch M,Kaden D,Pamporaki C,et al. Overnight/first-morning urine free metanephrines and methoxytyramine for diagnosis of pheochromocytoma and paraganglioma:is this an option?[J].Eur J Endocrinol,2020,182(5):499-509.DOI:10.1530/EJE-19-1016.
[14] Rao D,Peitzsch M,Prejbisz A,et al. Plasma methoxytyramine:clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma[J].Eur J Endocrinol,2017,177(2):103-113.DOI:10.1530/EJE-17-0077.
[15] Peitzsch M,Prejbisz A,Kroiss M,et al. Analysis of plasma 3-methoxytyramine,normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry:utility for diagnosis of dopamine-producing metastatic phaeochromocytoma[J].Ann Clin Biochem,2013,50(Pt 2):147-155.DOI:10.1258/acb.2012.012112.
[16] Marotta V,Zatelli MC,Sciammarella C,et al. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms:more flaws than fame[J].Endocr Relat Cancer,2018,25(1):R11-R29.DOI:10.1530/ERC-17-0269.
[17] Grossrubatscher E,Dalino P,Vignati F,et al. The role of chromogranin A in the management of patients with phaeochromocytoma[J].Clin Endocrinol(Oxf),2006,65(3):287-293.DOI:10.1111/j.1365-2265.2006.02591.x.
[18] Unger N,Hinrichs J,Deutschbein T,et al. Plasma and urinary metanephrines determined by an enzyme immunoassay,but not serum chromogranin A for the diagnosis of pheochromocytoma in patients with adrenal mass[J].Exp Clin Endocrinol Diabetes,2012,120(8):494-500.DOI:10.1055/s-0032-1309007.
[19] Giovanella L,Ceriani L. Serum chromogranin-alpha immunoradiometric assay in the diagnosis of pheochromocytoma[J].Int J Biol Markers,2002,17(2):130-134.DOI:10.5301/jbm.2008.1853.
[20] Plouin PF,Amar L,Dekkers OM,et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma[J].Eur J Endocrinol,2016,174(5):G1-G10.DOI:10.1530/EJE-16-0033.
[21] Zuber S,Wesley R,Prodanov T,et al. Clinical utility of chromogranin A in SDHx-related paragangliomas[J].Eur J Clin Invest,2014,44(4):365-371.DOI:10.1111/eci.12245.
[22] 冯超. 嗜铬粒蛋白A的生物学特性与嗜铬细胞瘤诊断的相关研究[D]. 北京:中国协和医科大学,2008,5-6.
[23] Peaston RT,Graham KS,Chambers E,et al. Performance of plasma free metanephrines measured by liquid chromatography-tandem mass spectrometry in the diagnosis of pheochromocytoma[J].Clin Chim Acta,2010,411(7-8):546-552.DOI:10.1016/j.cca.2010.01.012.
[24] Taylor RL,Singh RJ. Validation of liquid chromatography-tandem mass spectrometry method for analysis of urinary conjugated metanephrine and normetanephrine for screening of pheochromocytoma[J].Clin Chem,2002,48(3):533-539.DOI:10.1093/clinchem/48.3.533.
相似文献/References:
[1]马晓森,童安莉.嗜铬细胞瘤分子病因学研究进展[J].国际内分泌代谢杂志,2021,41(02):82.[doi:10.3760/cma.j.cn121383-20200630-06087]
Ma Xiaosen,Tong Anli..Research progress on the molecular etiology of pheochromocytoma[J].International Journal of Endocrinology and Metabolism,2021,41(02):82.[doi:10.3760/cma.j.cn121383-20200630-06087]
[2]张越,周波.巨大囊性嗜铬细胞瘤/副神经节瘤诊治研究进展[J].国际内分泌代谢杂志,2021,41(03):212.[doi:10.3760/cma.j.cn121383-20200922-09042]
Zhang Yue,Zhou Bo..Research progress on diagnosis and treatment of giant cystic pheochromocytoma/paraganglioma[J].International Journal of Endocrinology and Metabolism,2021,41(02):212.[doi:10.3760/cma.j.cn121383-20200922-09042]
[3]刘海春 高洪波 李赟 李隆敏 邵玉军.基因突变对嗜铬细胞瘤/副神经节瘤临床特征及预后的影响[J].国际内分泌代谢杂志,2023,43(05):392.[doi:10.3760/cma.j.cn121383-20221029-10044]
Liu Haichun,Gao Hongbo,Li Yun,et al.Effect of gene mutations on clinical features and prognosis of pheochromocytoma/paraganglioma[J].International Journal of Endocrinology and Metabolism,2023,43(02):392.[doi:10.3760/cma.j.cn121383-20221029-10044]